Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line

Miao,Ruizheng; Xu,Tao; Liu,Liqing; Wang,Meng; Jiang,Yanming; Li,Jianfeng; Guo,Renle

doi:10.3892/etm.2011.227

Rosiglitazone and retinoic acid inhibit proliferation and induce apoptosis in the HCT-15 human colorectal cancer cell line

Authors:
- Ruizheng Miao
- Tao Xu
- Liqing Liu
- Meng Wang
- Yanming Jiang
- Jianfeng Li
- Renle Guo
View Affiliations

Affiliations: Department of Surgery, Shandong Provincial Hospital, Shandong University, Shandong 250021, P.R. China, Central Laboratory, Shandong Provincial Hospital, Shandong University, Shandong 250021, P.R. China
Published online on: March 10, 2011 https://doi.org/10.3892/etm.2011.227
Pages: 413-417

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to explore the effects of rosiglitazone (RSG) in combination with all-trans retinoic acid (ATRA) on the proliferation and apoptosis of the HCT-15 human colorectal cancer cell line. HCT-15 cells were divided into a blank control group, a vehicle control group and experimental groups (RSG only or ATRA only or RSG plus ATRA). Growth inhibition was examined using the MTT assay. Apoptosis and cell cycle progression were examined by flow cytometry. The expression of COX-2, MMP-7 and TIMP-1 was examined by immunocytochemistry. RSG alone inhibited HCT-15 cell proliferation in a concentration- and time-dependent manner (P<0.05). The combination of RSG and ATRA exhibited significant synergy (q>1.15). RSG or ATRA alone effectively increased the proportion of cells in the G0/G1 phase and decreased the proportion of cells in the S phase, thus inducing apoptosis (P<0.05). The combination of RSG and ATRA resulted in even stronger G1 cell cycle arrest (P<0.05). HCT-15 cells expressed COX-2, MMP-7 and TIMP-1, with positive expression rates in the control group of 66.79, 73.21 and 64.08%, respectively. After the combined application of RSG and ATRA, the positive rates significantly declined to only 19.33, 20.58 and 13.13%, respectively (P<0.01). In conclusion, the combination of RSG and ATRA reduced the expression of COX-2, MMP-7 and TIMP-1, caused cell cycle arrest at the G1 phase and induced apoptosis, which resulted in the inhibition of cell proliferation in the HCT-15 human colorectal cancer cell line.

View Figures

View References

1.	Issemann I and Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:645–650. 1990. View Article : Google Scholar : PubMed/NCBI
2.	Kersten S, Desvergne B and Wahli W: Roles of PPARs in health and disease. Nature. 40:421–424. 2000.
3.	Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman DS, Oh W, Demetri G, Figg WD, Zhou XP, Eng C, Spiegelman BM and Kantoff PW: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA. 97:10990–10995. 2000. View Article : Google Scholar : PubMed/NCBI
4.	Nagamine M, Okumura T, Tanno S, Sawamukai M, Motomura W, Takahashi N and Kohgo Y: PPARgamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci. 94:338–343. 2003. View Article : Google Scholar : PubMed/NCBI
5.	Heaney AP, Fernando M and Melmed S: PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest. 111:1381–1388. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Yoshimura R, Matsuymma M, Segawa Y, Hase T, Mitsuhashi M, Tsuchida K, Wada S, Kawahito Y, Sano H and Nakatani T: Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int J Cancer. 104:597–602. 2003. View Article : Google Scholar : PubMed/NCBI
7.	Guan YF, Zhang YH, Breyer RM, Davis L and Breyer MD: Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia. 1:330–339. 1999. View Article : Google Scholar : PubMed/NCBI
8.	Faueonnet S, Lascombe I, Chabannes E, Adessi GL, Desvergne B, Wahli W and Bittard H: Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem. 277:23534–23543. 2002. View Article : Google Scholar
9.	Elstner E, Williamson EA, Zang C, Fritz J, Heber D, Fenner M, Possinger K and Koeffler HP: Novel therapeutic approach: ligands for PPARgamma and retinoid receptors induce apoptosis in bcl-2-positive human breast cancer cells. Breast Cancer Res Treat. 74:155–165. 2002. View Article : Google Scholar
10.	Zhou X, Zheng Q, Zhao X and Ma H: The inhibitory effect of elemene combined with tamoxifen on breast cancer cell line MCF-7. J Xi’an Jiaotong Univ Med Sci. 28:74–77. 2007.
11.	Chawla A, Schwarz EJ, Dimaculangan DD and Lazar MA: Peroxisome proliferator activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology. 135:798–800. 1994.
12.	Theocharis S, Giaginis C, Parasi A, Margeli A, Kakisis J, Agapitos E and Kouraklis G: Expression of peroxisome proliferator-activated receptor-gamma in colon cancer: correlation with histopathological parameters, cell cycle-related molecules, and patient survival. Dig Dis Sci. 52:2305–2311. 2007. View Article : Google Scholar
13.	Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D and Koeffler HP: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 95:8806–8811. 1998. View Article : Google Scholar : PubMed/NCBI
14.	Shimada T, Kojima K, Yoshiura K, Hiraishi H and Terano A: Characteristics of the peroxisome proliferator-activated receptor γ (PPARγ) ligand induced apoptosis in colon cancer cells. Gut. 50:658–664. 2002.
15.	Chang TH and Szabo E: Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res. 60:1129–1138. 2000.
16.	Motomura W, Okumura T, Takahashi N, Obara T and Kohgo Y: Activation of peroxisome proliferator-activated receptorγ by troglitazone inhibits cell growth through the increases of P27kipl in human pancreatic carcinoma cells. Cancer Res. 60:5558–5564. 2000.
17.	Liu JJ, Liu PQ, Lin DJ, Xiao RZ, Huang M, Li XD, He Y and Huang RW: Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonist-induced apoptosis in human monocyte leukemia cells in vitro. Ann Hematol. 86:173–183. 2007. View Article : Google Scholar
18.	Yoshida K, Tanabe K, Fujii D, Oue N, Yasui W and Toge T: Induction mechanism of apoptosis by troglitazone through peroxisome proliferator-activated receptor-gamma in gastric carcinoma cells. Anticancer Res. 23:267–273. 2003.
19.	Murata H, Kawano S, Tsuji S, Tsuji M, Sawaoka H, Kimura Y, Shiozaki H and Hori M: Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol. 94:451–460. 1999. View Article : Google Scholar : PubMed/NCBI
20.	Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K and Yachi A: Expression of MMP-7 mRNA in human colorectal cancers. Int J Cancer. 54:614–619. 1993. View Article : Google Scholar : PubMed/NCBI
21.	McDonnell S, Naver M, Coffey RJ Jr and Matrisian LM: Expression and localization of the matrix metalloproteinase pump21 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog. 4:527–536. 1991. View Article : Google Scholar : PubMed/NCBI
22.	Baker AH, George SJ, Zaltsman AB, Murphy G and Newby AC: Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by over-expression of TIMP-3. Br J Cancer. 79:1347–1355. 1999. View Article : Google Scholar : PubMed/NCBI